This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended) A method for treating schizophrenia a neurological disorder in a subject suffering therefrom, the method comprising administering to the subject an effective amount of a SLURP-1 polypeptide comprising the amino acid sequence of SEQ ID NO: 2,

thereby treating schizophrenia in the subject to a subject suffering from said neurological disorder.

2. (Currently amended) The method of claim 1, wherein schizophrenia a neurological disorder comprises a pathology caused by dysfunction of an acetylcholine receptor selected from the group consisting of an alpha 7 nicotinic acetylcholine receptor and an alpha 7 nicotinic acetylcholine receptor related protein.

3-5. (Canceled).

6. (Currently amended) The method of claim 1, wherein the effective amount of the SLURP-1 polypeptide is from about 1.0 pM to about 10 μM.

7. (Currently amended) The method of claim 1, wherein the effective amount of the SLURP-1 polypeptide is administered to the subject by a method selected from the group consisting of orally, intravenously, intraperitoneally, intranasally, and intramuscularly.

8. (Canceled).

9. (Currently amended). A method for treating schizophrenia in a subject suffering therefrom, the method comprising administering to the subject an effective amount of a SLURP-1 polypeptide comprising amino acids 23-103 of the amino acid sequence of SEQ ID NO: 2,

thereby treating schizophrenia in the subject The method of claim 1, wherein the SLURP-1 is in a mature form.

10. (Currently amended). The method of claim 9, wherein the mature form of SLURP-1 comprises comprising administering to the subject an effective amount of a SLURP-1 polypeptide consisting of amino acids 23-103 of SEQ ID NO: 2 SLURP-1.

11. (Original). The method of claim 1, wherein the subject is a mammal.

12. (Original). The method of claim 11, wherein the mammal is a human.

13-59. (Canceled).

60. (Currently amended). A method of treating schizophrenia a neurological disorder caused by the dysfunction of the alpha 7 nicotinic acetylcholine receptor in a subject suffering therefrom, the method comprising administering to the subject a composition comprising an effective amount of a peptide mimetic of the SLURP-1 polypeptide of SEQ ID NO: 2 and a carrier, wherein the composition modulates the function of an alpha 7 nicotinic acetylcholine receptor or of a related protein,

thereby treating schizophrenia in the subject the composition of claim 58 to a subject suffering from said neurological disorder.

61-79. (Canceled).

80. (New). A method for treating schizophrenia in a subject suffering therefrom, the method comprising administering to the subject an effective amount of a SLURP-1 polypeptide at least 90% identical to the amino acid sequence of SEQ ID NO: 2,
thereby treating schizophrenia in the subject.

81. (New). The method of claim 80, comprising administering to the subject an effective amount of a SLURP-1 polypeptide at least 95% identical to the amino acid sequence of SEQ ID NO: 2.

82. (New). The method of claim 80, comprising administering to the subject an effective amount of a SLURP-1 polypeptide at least 99% identical to the amino acid sequence of SEQ ID NO: 2.

83. (New). The method of claim 60, wherein the composition further comprises a SLURP-1 polypeptide comprising the amino acid sequence of SEQ ID NO: 2 or a SLURP-1 polypeptide comprising amino acids 23-103 of the amino acid sequence of SEQ ID NO: 2.